Printer Friendly

Verastem signs commercialization agreement with Sanofi for Copiktra in EMEA.

Verastem (VSTM) announced their entry into an exclusive licensing agreement with Sanofi (SNY) to develop and commercialize Verastem Oncology's COPIKTRA, or duvelisib, an oral inhibitor of phosphoinositide 3-kinase, and the first approved dual inhibitor of PI3K-delta and PI3K-gamma, for the treatment of all oncology indications in Russia and CIS, Turkey, the Middle East and Africa. Under the terms of the agreement, Verastem Oncology shall receive an upfront payment of $5M. Verastem Oncology is also eligible to receive up to an additional $42M in development and sales milestone payments, plus double-digit percentage royalties based on future net sales of COPIKTRA in the licensed territories. Sanofi will receive exclusive rights to develop and commercialize COPIKTRA, and hold the marketing authorization and product license for COPIKTRA, in the licensed territories. Sanofi will also have the right to collaborate with Verastem Oncology on certain global development and clinical trial activities.

COPYRIGHT 2019 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Date:Jul 25, 2019
Previous Article:MaxLinear reports Q2 EPS 22c, consensus 21c.
Next Article:Forward Air reports Q2 EPS 78c, consensus 79c.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters